Palvella Therapeutics Financial Statements
NASDAQ: PVLAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
138.77+7.43 (+5.66%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Palvella Therapeutics revenue and earnings
Palvella Therapeutics reported a net loss of $41.7 million, compared with a loss of $17.4 million a year earlier. Diluted earnings per share came in at -$3.71.
Summary generated from market data by MetaCap's automated system. Methodology
Palvella Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 42.81M | 25.90M | 31.42M | 29.32M | 46.28M | 29.10M | 25.27M | 5.83M |
| Revenue growth (YoY) | — | — | +65.28% | -17.56% | +7.14% | -36.64% | +59.03% | +15.14% | +333.46% | +98.88% |
| Operating Expenses | 38.60M | 14.10M | 11.87M | 69.38M | 83.25M | 63.24M | 73.44M | 59.93M | 39.87M | 28.59M |
| Research & Development | 22.84M | 8.15M | 8.79M | 52.98M | 66.66M | 46.53M | 55.00M | 41.49M | 22.29M | 19.70M |
| Operating Income | -38.60M | -14.10M | -11.87M | -43.47M | -51.83M | -33.92M | -27.16M | -30.83M | -14.59M | -22.76M |
| Interest Expense | 0 | 430.00K | 0 | — | — | — | — | — | — | — |
| Other Income (Expense) | 727.00K | -131.00K | 712.00K | 1.30M | 2.40M | -3.66M | -26.00K | 1.80M | -2.10M | 120.00K |
| Pretax Income | -41.72M | -17.43M | 18.69M | -33.28M | -45.74M | -37.07M | -25.47M | -27.07M | -16.54M | -22.64M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 164.00K | 0 | -312.00K | 1.10M | 162.00K |
| Net Income | -41.72M | -17.43M | 18.69M | -33.28M | -45.74M | -37.23M | -25.47M | -26.75M | -17.65M | -22.80M |
| Net Income growth (YoY) | — | -193.27% | — | — | — | — | — | — | — | — |
| EPS (Basic) | -3.71 | -7.83 | 2.19 | -0.45 | -0.71 | -0.68 | -0.56 | -0.50 | -0.40 | -0.55 |
| EPS (Diluted) | -3.71 | -7.83 | 2.17 | — | -0.71 | -0.68 | -0.56 | -0.50 | -0.40 | -0.55 |
| Shares Outstanding (Basic) | 11.25M | 2.23M | 1.77M | 74.17M | 64.55M | 54.48M | 50.63M | 53.08M | 43.93M | 41.71M |
| Shares Outstanding (Diluted) | 11.25M | 2.23M | 1.79M | — | 64.55M | 54.48M | 50.63M | 53.08M | 43.93M | 41.71M |
| EBITDA | — | — | -9.96M | -40.70M | -49.37M | -31.82M | -26.56M | -30.26M | -14.22M | -22.40M |
| Operating Margin | — | — | -27.72% | -167.84% | -164.97% | -115.68% | -58.68% | -105.94% | -57.74% | -390.31% |
| Net Margin | — | — | 43.66% | -128.47% | -145.58% | -126.97% | -55.03% | -91.93% | -69.82% | -391.00% |
This table shows 10 annual periods of Palvella Therapeutics's income statement, from FY 2025 back to FY 2016, across 16 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow PVLA's reporting calendar. What is a income statement?